Terkko Navigator / Tikkanen, M(atti) J.*

Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.

Increased Body Fat Mass and Androgen Metabolism - a Twin Study in Healthy Young Women.

Comparison of Low-density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial.

Estrogen biosynthesis in breast adipose tissue during menstrual cycle in women with and without breast cancer.

Estrogen Metabolism in Abdominal Subcutaneous and Visceral Adipose Tissue in Postmenopausal Women.

Plasma enterolactone and risk of prostate cancer in middle-aged Swedish men.

Metabolism of Sex Steroids Is Influenced by Acquired Adiposity-a Study of Young Adult Male Monozygotic Twin Pairs.

Attitudes and actions: A survey to assess statin use among Finnish patients with increased risk for cardiovascular events.

Can LDL cholesterol be too low? Possible risks of extremely low levels.

Response to the comments by Per E. Lønning.

Steroid sulfatase activity in subcutaneous and visceral adipose tissue: a comparison between pre- and postmenopausal women.

QUANTITATIVE DETERMINATION OF ESTRONE BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY IN SUBCUTANEOUS ADIPOSE TISSUE FROM THE BREAST IN MENOPAUSAL WOMEN.

Novel structural features increase the antioxidant effect of estrogen analogues on low density lipoprotein.

The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.

High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.

Breast Adipose Tissue Estrogen Metabolism in Postmenopausal Women with or without Breast Cancer.

Systolic blood pressure and fatty acid-binding protein 4 predict pregnancy-induced hypertension in overweight nulliparous women.

The Orientation and Dynamics of Estradiol and Estradiol Oleate in Lipid Membranes and HDL Disc Models.

Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia.

Plasma alkylresorcinol metabolites as biomarkers for whole-grain intake and their association with prostate cancer: a Swedish nested case-control study.

17β-ESTRADIOL AND ESTRADIOL FATTY ACYL ESTERS AND ESTROGEN-CONVERTING ENZYME EXPRESSION IN ADIPOSE TISSUE IN OBESE MEN AND WOMEN.

Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.

Elevated serum angiopoietin-like protein 6 in women with subsequent pregnancy-induced hypertension: a preliminary study.

The impact of gender and serum estradiol levels on HDL-mediated reverse cholesterol transport.

Fatty acyl esterification and deesterification of 17?-estradiol in human breast subcutaneous adipose tissue.

Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis.

Rye bread intake improves oxidation resistance of LDL in healthy humans.

Are there endogenous estrone fatty acyl esters in human plasma or ovarian follicular fluid?

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

Pharmacokinetics of alkylresorcinol metabolites in human urine.

LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study.

Quantitative determination of dehydroepiandrosterone fatty acyl esters in human female adipose tissue and serum using mass spectrometric methods.

Fatty acid esters of steroids: synthesis and metabolism in lipoproteins and adipose tissue.

The effect of high-fiber rye bread enriched with nonesterified plant sterols on major serum lipids and apolipoproteins in normocholesterolemic individuals.

DEHYDROEPIANDROSTERONE FATTY ACYL ESTERS IN HIGH DENSITY LIPOPROTEIN: INTERACTION WITH HUMAN VASCULAR ENDOTHELIAL CELLS AND VASCULAR RESPONSES EX VIVO.

Hormonal and metabolic characteristics of premenopausal women with a history of preeclamptic pregnancy.

Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] T

Hot flushes and biochemical markers for cardiovascular disease: a randomized trial on hormone therapy.

Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial.

Total Cardiovascular Disease Burden: Comparing Intensive With Moderate Statin Therapy Insights From the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) Trial.

Plasma pharmacokinetics of alkylresorcinol metabolites: new candidate biomarkers for whole-grain rye and wheat intake.

Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease.

Biochemical markers for cardiovascular disease in recently postmenopausal women with or without hot flashes.

HDL-associated dehydroepiandrosterone fatty acyl esters: Enhancement of vasodilatory effect of HDL.

Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction.

Human macrophage cholesterol efflux potential is enhanced by HDL-associated 17-beta estradiol fatty acyl esters.

Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL).

Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study.

Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged <65 Versus >/=65 Years With Coronary Heart Disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study).

Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. insights from the incremental decrease in end-points through aggressive lipid-lowering trial (IDEAL).